InterMune ex indicted in off-label probe

Think off-label marketing isn't a big deal? Tell that to InterMune's ex-CEO, who was indicted for trumping up the efficacy of his lung-disease product Actimmune and marketing it for an unapproved use. Prosecutors allege Dr. W. Scott Harkonen lied in a press release, saying that Actimmune extended the lives of patients with a fatal lung disease known as IPF. By touting Actimmune as an IPF remedy, they say, he was violating FDA rules against off-label marketing.

Harkonen's lawyer says there is data showing that Actimmune helps IPF patients. "By this indictment, the government is trying to criminalize an important potentially life-saving scientific debate," Brosnahan said. InterMune already paid $37 million to settle off-label marketing claims. Plus, the company said in a statement, Harkonen has left the building; he's now CEO of CoMentis, which says it's standing by its leader.

- read the San Jose Mercury News report

Suggested Articles

Pfizer’s Ibrance has met with success in breast cancer since breaking onto the scene in 2015. But its first foray into early breast cancer was a bust.

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.